[1]
|
Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., et al. (2004) Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. New England Journal of Medicine, 350, 1828-1837.
https://doi.org/10.1056/NEJMoa032520
|
[2]
|
Martelli, M., Ferreri, A.J., Agostinelli, C., Di Rocco, A., Pfreundschuh, M. and Pileri, S.A. (2013) Diffuse Large B-Cell Lymphoma. Critical Reviews in Oncology/Hematology, 87, 146-171.
https://doi.org/10.1016/j.critrevonc.2012.12.009
|
[3]
|
Molina, A. (2008) A Decade of Rituximab: Improving Sur-vival Outcomes in Non-Hodgkin’s Lymphoma. Annual Review of Medicine, 59, 237-250. https://doi.org/10.1146/annurev.med.59.060906.220345
|
[4]
|
Younes, A., Thieblemont, C., Morschhauser, F., et al. (2014) Combination of Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) for Treatment-Naive Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma: A Non-Randomised, Phase 1b Study. The Lancet Oncology, 15, 1019-1026.
https://doi.org/10.1016/S1470-2045(14)70311-0
|
[5]
|
Lossos, I.S. and Morgensztern, D. (2006) Prognostic Bi-omarkers in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 24, 995-1007. https://doi.org/10.1200/JCO.2005.02.4786
|
[6]
|
Mociková, H. (2010) Prognostic Significance of Absolute Lym-phocyte Count and Lymphocyte Subsets in Lymphomas. Prague Medical Report, 111, 5-11.
http://pmr.cuni.cz/Data/Files/PragueMedicalReport/pmr_111_2010_1/pmr2010a0001.pdf
|
[7]
|
Galand, C., Donnou, S., Molina, T.J., Fridman, W.H., Fisson, S. and Sautès-Fridman, C. (2012) Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in Immu-nology, 3, Article 98. https://doi.org/10.3389/fimmu.2012.00098
|
[8]
|
Wahlin, B.E., Sander, B., Christensson, B. and Kimby, E. (2007) CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma. Clinical Cancer Research, 13, 388-397. https://doi.org/10.1158/1078-0432.CCR-06-1734
|
[9]
|
D’Arena, G., Vitale, C., Coscia, M., et al. (2017) Regulato-ry T Cells and Their Prognostic Relevance in Hematologic Malignancies. Journal of Immunology Research, 2017, Article ID: 1832968. https://doi.org/10.1155/2017/1832968
|
[10]
|
Kusano, Y., Yokoyama, M., Terui, Y., et al. (2017) Low Absolute Peripheral Blood CD4+ T-Cell Count Predicts Poor Prognosis in R-CHOP-Treated Patients with Diffuse Large B-Cell Lymphoma. Blood Cancer Journal, 7, e558.
https://doi.org/10.1038/bcj.2017.37
|
[11]
|
Chraa, D., Naim, A., Olive, D. and Badou, A. (2019) T Lymphocyte Subsets in Cancer Immunity: Friends or Foes. Journal of Leukocyte Biology, 105, 243-255. https://doi.org/10.1002/JLB.MR0318-097R
|
[12]
|
Palma, M., Gentilcore, G., Heimersson, K., et al. (2017) T Cells in Chronic Lymphocytic Leukemia Display Dysregulated Expression of Immune Checkpoints and Activation Markers. Haematologica, 102, 562-572.
https://doi.org/10.3324/haematol.2016.151100
|
[13]
|
Dobrzanski, M.J. (2013) Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy. Frontiers in Oncology, 3, Article 63. https://doi.org/10.3389/fonc.2013.00063
|
[14]
|
Fridman, W.H., Pagès, F., Sautès-Fridman, C. and Galon, J. (2012) The Immune Contexture in Human Tumours: Impact on Clinical Outcome. Nature Reviews Cancer, 12, 298-306. https://doi.org/10.1038/nrc3245
|
[15]
|
Battella, S., Cox, M.C., La Scaleia, R., et al. (2017) Peripheral Blood T Cell Alterations in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients and Their Long-Term Dynamics Upon Rituximab-Based Chemoimmunotherapy. Cancer Immunology, Immunotherapy, 66, 1295-1306. https://doi.org/10.1007/s00262-017-2026-7
|
[16]
|
Mori, T., Takada, R., Watanabe, R., Okamoto, S. and Ikeda, Y. (2001) T-Helper (Th)1/Th2 Imbalance in Patients with Previously Untreated B-Cell Diffuse Large Cell Lymphoma. Cancer Immunology, Immunotherapy, 56, 566-568.
https://doi.org/10.1007/s00262-001-0232-8
|
[17]
|
Sheng, L., Fu, D., Ca,o Y., et al. (2022) Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma with Multiple Abnormal Immunologic Markers. Frontiers in Oncology, 12, Article 790720.
https://doi.org/10.3389/fonc.2022.790720
|
[18]
|
Abès, R., Gélizé, E., Fridman, W.H. and Teillaud, J.-L. (2010) Long-Lasting Antitumor Protection by Anti-CD20 Antibody through Cellular Immune Response. Blood, 116, 926-934. https://doi.org/10.1182/blood-2009-10-248609
|
[19]
|
Weiner, G.J. (2010) Rituximab: Mechanism of Action. Semi-nars in Hematology, 47, 115-123.
https://doi.org/10.1053/j.seminhematol.2010.01.011
|
[20]
|
Yin, Q., Zha, X., Yang, L., et al. (2011) Generation of Diffuse Large B Cell Lymphoma-Associated Antigen-Specific Vα6/Vβ13+T Cells by TCR Gene Transfer. Journal of Hematology & Oncology, 4, Article No. 2.
https://Doi.Org/10.1186/1756-8722-4-2
|
[21]
|
Schreck, S., Friebel, D., Buettner, M., et al. (2009) Prognostic Impact of Tumour-Infiltrating Th2 and Regulatory T cells in Classical Hodgkin Lymphoma. Hematological Oncology, 27, 31-39. https://doi.org/10.1002/hon.878
|
[22]
|
Dehghani, M., Ramzi, M., Kalani, M., Golmoghaddam, H. and Arandi, N. (2022) Higher Peripheral Blood IFN-γ-/IL-4+ Th2 Lymphocytes Are Associated with Lower Rate of Relapse in Patients with Lymphoma. Immunological Investigations, 51, 452-463. https://doi.org/10.1080/08820139.2020.1840583
|
[23]
|
Yoon, N.K., Maresh, E.L., Shen, D., et al. (2010) Higher Levels of GATA3 Predict Better Survival in Women with Breast Cancer. Human Pathology, 41, 1794-1801. https://doi.org/10.1016/j.humpath.2010.06.010
|
[24]
|
Lorvik, K.B., Hammarström, C., Fauskanger, M., et al. (2016) Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an in Situ Inflammatory Immune Re-sponse. Cancer Research, 68, 64-76.
https://doi.org/10.1158/0008-5472.CAN-16-1219
|
[25]
|
Purwar, R., Schlapbach, C., Xiao, S., et al. (2012) Robust Tumor Immunity to Melanoma Mediated by Interleukin-9-Producing T Cells. Nature Medicine, 18, 1248-1253. https://doi.org/10.1038/nm.2856
|
[26]
|
Jones, E.A., Pringle, J.H., Angel, C.A. and Rees, R.C. (2002) Th1/Th2 Cy-tokine Expression and Its Relationship with Tumor Growth in B Cell Non-Hodgkin’s Lymphoma (NHL). Leukemia & Lymphoma, 43, 1313-1321.
https://doi.org/10.1080/10428190290026385
|
[27]
|
Kurtz, D.M., Tschetter, L.K., Allred, J.B., et al. (2007) Subcuta-neous Interleukin-4 (IL-4) for Relapsed and Resistant Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia & Lymphoma, 48, 1290-1298. https://doi.org/10.1080/10428190701355028
|
[28]
|
Yin, Q., Chen, L., Li, Q., et al. (2014) Changes of T-Lymphocyte Subpopulation and Differential Expression Pattern of the T-Bet and GATA-3 Genes in Diffuse Large B-Cell Lymphoma Patients after Chemotherapy. Cancer Cell International, 14, Article No. 85. https://doi.org/10.1186/s12935-014-0085-9
|
[29]
|
Deligne, C., Metidji, A., Fridman, W.-H. and Teillaud, J.-L. (2015) Anti-CD20 Therapy Induces a Memory Th1 Response through the IFN-γ/IL-12 Axis and Prevents Protumor Regulatory T-Cell Expansion in Mice. Leukemia, 29, 947-957. https://doi.org/10.1038/leu.2014.275
|
[30]
|
Puzzolo, M.C., Del Giudice, I., Peragine, N., et al. (2021) TH2/TH1 Shift under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 11, Article 637186. https://doi.org/10.3389/fonc.2021.637186
|
[31]
|
Chang, C., Wu, S.-Y., Kang, Y.-W., et al. (2015) High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients with Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 144, 935-944.
https://doi.org/10.1309/AJCPUJGMVV6ZF4GG
|
[32]
|
Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S.A. and Dirnhofer, S. (2008) Correlation of High Numbers of Intratumoral FOXP3+ Regulatory T Cells with Improved Survival in Germinal Center-Like Diffuse Large B-Cell Lymphoma, Follicular Lymphoma and Classical Hodgkin’s Lymphoma. Haematologica, 93, 193-200.
https://doi.org/10.3324/haematol.11702
|
[33]
|
Dehghani, M., Kalani, M., Golmoghaddam, H., Ramzi, M. and Arandi, N. (2020) Aberrant Peripheral Blood CD4+ CD25+ FOXP3+ Regulatory T Cells/T Helper-17 Number Is Associated with the Outcome of Patients with Lymphoma. Cancer Immunology, Immunotherapy, 69, 1917-1928. https://doi.org/10.1007/s00262-020-02591-y
|